Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed melanoma meeting the following criteria:
• * Unresectable recurrent disease
• * Stage III or IV disease
• * Cutaneous, ocular, or mucosal melanoma
• Measurable disease as defined by the RECIST criteria
• HLA-A2 positive
• Prior brain metastases allowed provided adequate surgical or radiologic treatment for brain disease
• PATIENT CHARACTERISTICS:
• ECOG performance status 0 or 1
• WBC ≥ 3,000/mm³
• Lymphocytes ≥ 1,000/mm³
• Platelet count ≥ 100,000/mm³
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• AST and ALT ≤ 2.5 times ULN
• Lactic dehydrogenase ≤ 2.0 times ULN
• aPTT \< 40 seconds
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception for ≥ 1 week before, during, and for ≥ 2 weeks after completion of study therapy
• No conditions of immunosuppression
• Negative titers for antinuclear antibody (≤ 1/80) and antidouble stranded DNA (≤ 1/10)
• No serious illnesses including, but not limited to, any of the following:
• * Bleeding disorders
• * Autoimmune diseases
• * Severe obstructive or restrictive pulmonary diseases
• * Active systemic infections
• * Inflammatory bowel disorders
• No serious cardiovascular disease including, but not limited to, any of the following:
• * Uncontrolled congestive heart failure
• * Hypertension
• * Cardiac ischemia
• * Myocardial infarction,
• * Severe cardiac arrhythmia
• HIV1 and 2 negative
• HTLV-1 negative
• Hepatitis B and C negative
• No significant psychiatric disease, medical intervention, or other condition that, in the opinion of the principal investigator, would limit study compliance
• No active infection within the past week, including unexplained fever (temperature \> 38.1°C)
• PRIOR CONCURRENT THERAPY:
• Fully recovered from prior major surgery
• More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas), hormonal therapy, radiotherapy, or biological therapy
• More than 1 week since prior antibiotics
• More than 28 days since prior investigational agent
• No prior vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides alone or in combination
• * Patients with history of vaccination with peptides other than MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides allowed
• More than 4 weeks since prior and no concurrent systemic immunosuppressive therapy, including steroids
• * Patients on maintenance steroids given at physiologic doses because of adrenal insufficiency are eligible
• More than 2 weeks since prior and no concurrent treatment with systemic steroids, including oral steroids, continuous use of topical steroid creams or ointments, or any inhaled steroids
• No concurrent anticoagulants, except to keep an indwelling line patent
• No other concurrent anticancer therapy, including chemotherapy, immunotherapy, radiotherapy, experimental programs, and/or surgery